"Pharma Bro" Martin Shkreli's Reputation Is Getting The Way Of Jury Selection

"Pharma Bro" Martin Shkreli's Reputation Is Getting The Way Of Jury Selection

Of 178 potential jurors questioned in Brooklyn federal court on Monday, only about 40 made the first cut, as others were dismissed for various reasons, including their opinions of Shkreli, the New York Daily News reported.

"The defendant is the face of corporate greed in America", the man said.

The trial could last just over a month.

One woman mimicked throttling someone as she talked about Mr. Shkreli's raising the price of "the AIDS drug".

Blanton was one of several investors who collectively raised $3 million in 2011 to allow MSMB to launch its own drug company, Retrophin in 2011.

Shkreli was notorious before his arrest, after hiking prices in 2015 for Daraprim, which is used by many AIDS patients, to $750 per pill from $13.50 after obtaining the license for its manufacture.

Benjamin Brafman, who is representing Shkreli, told FiercePharma in an email that he objected to the private sidebars because he was concerned that the resulting press reports would prejudice the case going forward.

Another leadership test for Pelosi, who's weathered many
Seth Moulton, a former Marine and a rising party star, said the special elections should be a "wake-up call" for Democrats. Remarkably, for Nancy Pelosi , yes. "There are still a lot of races we've got to win", Stivers told reporters.

Specifically, prosecutors say, Shkreli violated federal law when he managed two hedge funds during that time and swindled investors.

But Shkreli's broader antics appear to have complicated jury selection. The Post put a picture of Shkreli on the cover Tuesday and said of the jurors who were excused: "They all hate him". Five counts each carry maximum sentences of 20 years in prison; the other three are a maximum of five years each.

In February, during a speech at Harvard, Shkreli tried to defend his long-held position that increasing the price of Daraprim was necessary to raise funding for research aimed at developing more drugs to treat neglected conditions.

And Turing is far from shaking off its association with Shkreli. He denies the charges, which relate to his time running two hedge funds and at Retrophin, a drug company. Turing did not immediately respond to a request for comment from Fierce.

In April, a judge ruled that Shkreli could be tried separately from his former attorney, who has also been charged in the case.

Matsumoto seemed delighted when she finally came across a woman in her 20s who said she hadn't heard of Shkreli or his case.

Related news